In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography

European Radiology

Volumn 25, Issue 2, 2015, Pages 472-479

  Fuge, Felix ^a   Doleschel, Dennis ^a   Rix, Anne ^a   Gremse, Felix ^a   Wessner, Axel ^b   Winz, Oliver ^c   Mottaghy, Felix ^c   Lederle, Wiltrud ^a   Kiessling, Fabian ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Anaemia; DOTA; Epo; EpoR; Lung cancer

Indexed keywords

CARBOHYDRATE; ERYTHROPOIETIN RECEPTOR; HYDRAZIDE; RADIOPHARMACEUTICAL AGENT; TETRAXETAN RECOMBINANT ERYTHROPOIETIN GA 68; UNCLASSIFIED DRUG; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SPECIFICITY; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; KIDNEY; LIVER; MOUSE; MUSCLE; NON SMALL CELL LUNG CANCER; NONHUMAN; PET SCANNER; PLASMA HALF LIFE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; STAINING; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; EXPERIMENTAL NEOPLASM; HUMAN; LUNG TUMOR; METABOLISM; NEOPLASM; NUDE MOUSE; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ERYTHROPOIETIN; FEMALE; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 84920766743     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-014-3413-5     Document Type: Article

References (34)

1. Spivak JL (2005) The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 5:543–555
2. Sato Y, Yanagita M (2013) Renal anemia: from incurable to curable. Am J Physiol Renal Physiol 305:F1239–F1248
3. Henke M, Mattern D, Pepe M et al (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708–4713
4. Wright JR, Ung YC, Julian JA et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027–1032
5. Bohlius J, Schmidlin K, Brillant C et al (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373:1532–1542
6. Bohlius J, Wilson J, Seidenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714
7. Bennett CL, Silver SM, Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J Am Med Assoc 299:914–924
8. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H (2008) Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10:932–939
9. Belenkov AI, Shenouda G, Rizhevskaya E et al (2004) Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 3:1525–1532
10. Shiozawa Y, McGee S, Pienta MJ et al (2013) Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis. J Cell Biochem 114:2471–2478
11. Todaro M, Turdo A, Bartucci M et al (2013) Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res 73:6393–6400
12. Rózsás A, Berta J, Rojkó L et al (2013) Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma. PLoS ONE 8:e77459
13. Baltaziak M, Wincewicz A, Kanczuga-Koda L et al (2013) The relationships between hypoxia-dependent markers: HIF-1alpha, EPO and EPOR in colorectal cancer. Folia Histochem Cytobiol Pol Acad Sci Pol Histochem Cytochem Soc 51:320–325
14. Ferracin M, Bassi C, Pedriali M et al (2013) miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol Cancer 12:130
15. Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ (2013) Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. J Hematol Oncol 6:65
16. Elliott S, Sinclair A, Collins H, Rice L, Jelkmann W (2014) Progress in detecting cell-surface protein receptors: the erythropoietin receptor example. Ann Hematol 93:181–192
17. Doleschel D, Mundigl O, Wessner A et al (2012) Targeted Near-Infrared Imaging of the Erythropoietin Receptor in Human Lung Cancer Xenografts. J Nucl Med 53:304–311
18. Ntziachristos V, Ripoll J, Wang LV, Weissleder R (2005) Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol 23:313–320
19. Yoshioka E, Kato K, Shindo H, Mitsuoka C, S.-I. Kitajima S-I, Ogata H et al: Pharmacokinetic study of darbepoetin alfa (2007) Absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats. Xenobiotica. 37(1)
20. dos Clemente GS, Duarte VLS (2011) Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours. Braz J Pharm Sci 47:83–88
21. Ehrenreich H, Degner D, Meller J et al (2004) Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 9:42–54
22. Fuge F, Weiler M, Gätjens J, Lammers T, Kiessling F (2013) Comparison and systematic optimization of synthetic protocols for DOTA–hydrazide generation. Tetrahedron Lett 54:918–920
23. Bauwens M, Chekol R, Vanbilloen H, Bormans G, Verbruggen A (2010) Optimal buffer choice of the radiosynthesis of 68Ga–Dotatoc for clinical application. Nucl Med Commun 31:753–758
24. Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T et al (1991) The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 266:23022–23026
25. Tsuda E, Kawanishi G, Ueda M, Masuda S, Sasaki R (1990) The role of carbohydrate in recombinant human erythropoietin. Eur J Biochem 188:405–411
26. Kunjachan S, Gremse F, Theek B et al (2013) Noninvasive optical imaging of nanomedicine biodistribution. ACS Nano 7:252–262
27. Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G et al (2009) Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci 98:2198–2211
28. Blom E, Velikyan I, Estrada S, Hall H, Muhammad T, Ding C et al (2012) 68Ga-Labeling of RGD peptides and biodistribution. Int J Clin Exp Med 5:165–172
29. Ranyuk E, Lebel R, Bérubé-Lauzière Y, Klarskov K, Lecomte R, van Lier JE et al (2013) 68Ga/DOTA- and 64Cu/NOTA-Phthalocyanine Conjugates as Fluorescent/PET Bimodal Imaging Probes. Bioconjug Chem 24:1624–1633
30. Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C et al (2011) [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. Eur J Nucl Med Mol Imaging 38:1303–1312
31. Zhang Y, Hong H, Engle JW, Bean J, Yang Y, Leigh BR et al (2011) Positron Emission Tomography Imaging of CD105 Expression with a 64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA. PLoS ONE 6:e28005
32. Jelkmann W (2002) The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 69:265–274
33. Oxboel J, Brandt-Larsen M, Schjoeth-Eskesen C et al (2014) Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors. Nucl Med Biol 41:259–267
34. Kang CM, Kim S-M, Koo H-J et al (2013) In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. Eur J Nucl Med Mol Imaging 40:198–206